Prognosis factors and predictive signs of malignancy in dermatomyositis.

被引:0
|
作者
Gallais, V [1 ]
Crickx, B [1 ]
Belaich, S [1 ]
机构
[1] HOP BICHAT,DERMATOL SERV,F-75018 PARIS,FRANCE
来源
关键词
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Introduction: Prognosis in dermatomyositis is severe, partly due to the development of cancer. The aim of this study was to identify factors predicting cancer development and assess factors predicting reduced survival rate. Patients and methods: A retrospective analysis of 32 cases of dermatmyositis diagnosed on the basis of the Bohan and Peter criteria was performed. Diagnosis was certain in 7 cases, probable in 13 and possible in 5. Then were thus 7 cases of pure cutaneous dermatomyositis. Clinical and laboratory data were compared between patients with and without cancer and between deceased and surviving patients. Results: Overall mortality was 37.5% at 4 years, confirming the gravity of dermatomyositis. Malignancy developed in 9 patients (28.1%) leading to death in all cases, within 18 months in 8. Amyopathic dermatomyositis was observed in 2 of these patients. Necrotic skin ulcerations (p < 0.01) and pruritis (p < 0.05) were significant predictive factors for the development of cancer. Poor prognosis factors were malignancy (p < 0.001), necrotic skin ulcerations (p < 0.01), and pruritis (p < 0.05). Conclusion: Prognosis is poor in certain sub-groups of patients with dermatomyositis. Such patients can be identified on the basis of skin lesions, notable necrotic ulcerations.
引用
收藏
页码:722 / 726
页数:5
相关论文
共 50 条
  • [31] Epidermal necrosis as a predictive sign of malignancy in adult dermatomyositis
    Mautner, GH
    Grossman, ME
    Silvers, DN
    Rabinowitz, A
    Mowad, CM
    Johnson, BL
    CUTIS, 1998, 61 (04): : 190 - 194
  • [32] Systemic Treatment for Clinically Amyopathic Dermatomyositis.
    Lin, Janice
    Femia, Alisa
    Patel, Mital
    Merola, Joseph
    Vleugels, Ruth Ann
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S969 - S969
  • [33] Juvenile dermatomyositis. Where are we now?
    McCann, L. J.
    Livermore, P.
    Wilkinson, M. G. Ll.
    Wedderburn, L. R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (02) : 394 - 403
  • [34] Spontaneous pneumomediastinum and dermatomyositis. A case report
    Fonseca Fernandez, Teresa
    Bouza Jimenez, Yanelka
    Rodriguez Zulueta, Yanet
    Munoz Morales, Alejandro
    MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2021, 19 (04): : 663 - 673
  • [35] A pilot study of eculizumab in patients with dermatomyositis.
    Takada, K
    Bookbinder, S
    Furie, R
    Oddis, C
    Mojcik, C
    Bombara, M
    Plotz, P
    Kissel, J
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S489 - S489
  • [36] An article on the so-called dermatomyositis.
    Horner, O
    BEITRAGE ZUR PATHOLOGISCHEN ANATOMIE UND ZUR ALLGEMEINEN PATHOLOGIE, 1939, 103 (02): : 300 - 307
  • [37] Intravenous immunoglobulins in the treatment of polymyositis and dermatomyositis.
    Cherin, P
    ANNALES DE MEDECINE INTERNE, 2000, 151 : 48 - 50
  • [38] Bone mineral density in juvenile dermatomyositis.
    Stewart, WA
    Acott, P
    MacNeill, I
    Salisbury, S
    Lang, B
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S229 - S229
  • [39] Interstitial lung disease in polymyositis and dermatomyositis.
    Marie, I
    Dominique, S
    Rémy-Jardin, M
    Hatron, PY
    Hachulla, E
    REVUE DE MEDECINE INTERNE, 2001, 22 (11): : 1083 - 1096
  • [40] Lymphocyte characteristics in patients with polymyositis and dermatomyositis.
    Ishii, Wataru
    Matsuda, Masayuki
    Shimojima, Yasuhiro
    Mamura, Mizuko
    Goto, Daisuke
    Matsumoto, Isao
    Ito, Satoshi
    Tsutsumi, Akito
    Sumida, Takayuki
    Ikeda, Shu-ichi
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S662 - S662